EUSTAR数据库中系统性硬化症相关间质性肺病的区域差异分析
研究将EUSTAR数据库中系统性硬化症患者按七个地理区域分组,比较系统性硬化症相关间质性肺病的患病率、表型、治疗和预后。基线分析纳入9260例患者,生存分析纳入6732例;总体患病率为50.2%,各区域从44.0%至67.5%不等;不同区域管理差异显著,美洲(北美和南美)和中东随访结束时生存率最高,分别为85.8%和85.2%。
要点
- 系统性硬化症相关间质性肺病总体患病率为50.2%,各区域从44.0%至67.5%不等。
- 所有区域中抗拓扑异构酶抗体均与系统性硬化症相关间质性肺病相关。
- 美洲(北美和南美)与中东随访末生存率最高,分别为85.8%和85.2%。
核心结论
- 研究强调各区域在系统性硬化症相关间质性肺病的临床表现和预后方面存在关键差异。
- 研究显示不同区域对该病的管理差异很大,提示仍需努力实现该病治疗医学实践的标准化。
研究设计与样本
- 基于EUSTAR数据库,将系统性硬化症患者按七个预定地理区域分组,比较系统性硬化症相关间质性肺病患者的临床特征和生存情况。
- 基线分析纳入9260例系统性硬化症患者,生存分析纳入6732例。
主要发现
- 总体人群中系统性硬化症相关间质性肺病患病率为50.2%,从「西欧和北欧国家」的44.0%到「东欧、俄罗斯和波罗的海国家」的67.5%不等。
- 所有区域中抗拓扑异构酶抗体均与系统性硬化症相关间质性肺病相关。
- 基线时霉酚酸酯处方比例在「美洲(北美和南美)」为31.6%、在「中东」为31.7%,而在「亚洲和大洋洲」仅为4.3%(P <0.0001)。
- 「美洲(北美和南美)」和「中东」随访结束时生存率最高,分别为85.8%和85.2%。
临床怎么用
- 作者认为各区域在系统性硬化症相关间质性肺病管理上差异很大,提示仍需努力实现该病治疗医学实践的标准化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database. MATERIAL AND METHODS: Patients were clustered into seven geographical regions. Clinical characteristics and survival of patients with SSc-ILD were compared among these pre-determined regions. RESULTS: For baseline analyses, 9260 SSc patients were included, with 6732 for survival analyses. The prevalence of SSc-ILD in the overall population was 50.2%, ranging from 44.0% in 'Western Europe and Nordic countries' to 67.5% in 'Eastern European, Russia and Baltic countries'. In all regions, anti-topoisomerase antibodies were associated with SSc-ILD. Management also significantly differed; mycophenolate mofetil was prescribed at baseline in 31.6% of patients with SSc-ILD in 'America (North and South)' and 31.7% in 'Middle East' but only 4.3% in 'Asia and Oceania' (P <0.0001). Patients from 'America (North and South)' and 'Middle East' had the highest survival rate at the end of follow-up (85.8% and 85.2%, respectively). CONCLUSIONS: Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD. This work also demonstrates that the management of SSc-ILD is highly variable among the different regions considered, suggesting that efforts are still needed for the standardization of medical practice in the treatment of this disease.
引用
- Lescoat A, Huscher D, Schoof N, et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology (Oxford). 2023. PMID: 36222557. doi:10.1093/rheumatology/keac576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。